FIN-525 / Finch Therap - LARVOL DELTA

Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD (GlobeNewswire) - "Finch Therapeutics Group, Inc...announced that it will regain full development and commercial rights to FIN-524 (previously known as TAK-524) and FIN-525 from Takeda Pharmaceutical Company Limited ('Takeda')....FIN-524 and FIN-525 are investigational, orally administered targeted microbiome product candidates composed of bacterial strains selected for their potential immuno-modulatory properties."

Licensing / partnership • Crohn's disease • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis